Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension
Angiotensin receptor blockers (ARBs) have gained widespread use in clinical medicine during the past decade. Several large, prospective and randomized multi-center trials have led us to reconsider the role of ARBs in the treatment of hypertension. Firstly, in view of the favorable safety and side effect profile of ARBs, we recommend their use in hypertensive subjects in whom ACE inhibitors are indicated but are unable to tolerate agents of this type due to intractable cough. Secondly, in light of the results of the RENAAL and IDNT studies, we consider ARBs as the drug of choice in diabetic subjects with hypertension and proteinuria (> 300 mg/L). Thirdly, we view ACE inhibitors and ARBs as equally adequate for the treatment of diabetic patients with hypertension and microalbuminuria and recommend the use of the maximal allowable doses of these drugs in such patients. Finally, older hypertensive individuals with left ventricular hypertrophy should receive either ACE inhibitors or ARBs, as these drug classes presently appear to provide better overall protection than beta blockers or calcium channel blockers in this particular subgroup of patients.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2003 |
|---|---|
| Erschienen: |
2003 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
Harefuah - 142(2003), 4 vom: 25. Apr., Seite 309-11, 315 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Stern, Naftali [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 13.06.2003 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM125223374 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM125223374 | ||
| 003 | DE-627 | ||
| 005 | 20231222205244.0 | ||
| 007 | tu | ||
| 008 | 231222s2003 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n0418.xml |
| 035 | |a (DE-627)NLM125223374 | ||
| 035 | |a (NLM)12754885 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Stern, Naftali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2003 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Angiotensin receptor blockers (ARBs) have gained widespread use in clinical medicine during the past decade. Several large, prospective and randomized multi-center trials have led us to reconsider the role of ARBs in the treatment of hypertension. Firstly, in view of the favorable safety and side effect profile of ARBs, we recommend their use in hypertensive subjects in whom ACE inhibitors are indicated but are unable to tolerate agents of this type due to intractable cough. Secondly, in light of the results of the RENAAL and IDNT studies, we consider ARBs as the drug of choice in diabetic subjects with hypertension and proteinuria (> 300 mg/L). Thirdly, we view ACE inhibitors and ARBs as equally adequate for the treatment of diabetic patients with hypertension and microalbuminuria and recommend the use of the maximal allowable doses of these drugs in such patients. Finally, older hypertensive individuals with left ventricular hypertrophy should receive either ACE inhibitors or ARBs, as these drug classes presently appear to provide better overall protection than beta blockers or calcium channel blockers in this particular subgroup of patients | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Receptor, Angiotensin, Type 1 |2 NLM | |
| 650 | 7 | |a Ramipril |2 NLM | |
| 650 | 7 | |a L35JN3I7SJ |2 NLM | |
| 700 | 1 | |a Grossman, Ehud |e verfasserin |4 aut | |
| 700 | 0 | |a Israeli Society of Hypertension |e verfasserin |4 aut | |
| 700 | 0 | |a Israeli Society of Nephrology |e verfasserin |4 aut | |
| 700 | 0 | |a Israeli Diabetes Association |e verfasserin |4 aut | |
| 700 | 0 | |a Israeli Society of Cardiology |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 142(2003), 4 vom: 25. Apr., Seite 309-11, 315 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2003 |g number:4 |g day:25 |g month:04 |g pages:309-11, 315 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2003 |e 4 |b 25 |c 04 |h 309-11, 315 | ||